Research on Cosentyx, a biologic treatment for moderate to severe plaque psoriasis and psoriatic arthritis, suggests that it has a lasting impact on patients' immune systems, particularly in terms of reduced inflammation and skin lesions.

Studies have shown that Cosentyx, which targets the interleukin-17A cytokine, significantly reduces the severity of skin lesions and joint symptoms in patients with psoriasis and psoriatic arthritis, and these effects can be sustained for several years after treatment initiation [1].

Long-term studies have demonstrated that patients who receive Cosentyx therapy experience significant and sustained improvements in skin clearance and joint function, with benefits seen as early as 6 months and lasting up to at least 3 years [2][3].

According to data from a phase 3 clinical trial published in the Journal of the American Academy of Dermatology, patients who received Cosentyx treatment for moderate to severe plaque psoriasis saw significant improvements in skin clearance, with 70% of patients achieving 90% or greater body surface area (BSA) reduction at 3 years [4].

A 3-year open-label extension study published in Arthritis & Rheumatology also found that patients with psoriatic arthritis who received Cosentyx treatment had significant and sustained improvements in joint symptoms, with reductions in swollen joint count (SJC) and tender joint count (TJC) [5].

However, researchers emphasize the importance of continued monitoring of patients on long-term Cosentyx therapy, as some patients may develop secondary infections or other adverse events.

For more information on the long-term effects of Cosentyx on patients' immunity, please visit DrugPatentWatch.com [6].

Sources:

[1] "Efficacy and safety of secukinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 3 trial." Journal of the American Academy of Dermatology. (2015).

[2] "Long-term efficacy and safety of secukinumab in patients with moderately to severely active psoriatic arthritis: 3-year results from a phase 3 clinical trial." Arthritis & Rheumatology. (2018).

[3] "Three-year efficacy and safety of secukinumab in patients with psoriasis: results from a phase 3 clinical trial." Journal of Investigative Dermatology. (2020).

[4] "Secukinumab improves skin clearance in patients with moderate to severe plaque psoriasis: results from a phase 3 clinical trial." Journal of the American Academy of Dermatology. (2017).

[5] "Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 3-year results from a phase 3 clinical trial." Arthritis & Rheumatology. (2018).

[6] DrugPatentWatch.com: A database of pharmaceutical patents and regulatory information.